{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:17:08Z","timestamp":1790857028810,"version":"4.1.0"},"reference-count":236,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020723","name":"Chhatrapati Shahu Maharaj Research Training and Human Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["CAD106"],"award-info":[{"award-number":["CAD106"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.apsb.2024.11.016","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T02:01:23Z","timestamp":1732586483000},"page":"1281-1310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Comprehensive investigation of multiple targets in the development of newer drugs for the Alzheimer's disease"],"prefix":"10.1016","volume":"15","author":[{"given":"Patil","family":"Ashwini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodhankar","family":"Subhash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthal","family":"Amol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dileep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawar","family":"Atmaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9455-7958","authenticated-orcid":false,"given":"Kulkarni","family":"Ravindra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2024.11.016_bib1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/21645515.2019.1665453","article-title":"Rationale for the development of an Alzheimer's disease vaccine","volume":"16","author":"Kwan","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.apsb.2024.11.016_bib2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3389\/fnins.2019.00659","article-title":"Alzheimer disease pathogenesis: insights from molecular and cellular biology studies of oligomeric A\u03b2 and tau species","volume":"13","author":"Chen","year":"2019","journal-title":"Front Neurosci"},{"key":"10.1016\/j.apsb.2024.11.016_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ijge.2016.07.003","article-title":"New therapeutic Targets in Alzheimer's disease","volume":"11","author":"Coman","year":"2017","journal-title":"Int J Gerontol"},{"key":"10.1016\/j.apsb.2024.11.016_bib4","doi-asserted-by":"crossref","first-page":"902","DOI":"10.3389\/fphar.2019.00902","article-title":"Mitochondria as potential targets in Alzheimer disease therapy: an update","volume":"10","author":"Cenini","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2024.11.016_bib5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/1533317508328602","article-title":"Reviews: current concepts in Alzheimer's disease: a multidisciplinary review","volume":"24","author":"Minati","year":"2009","journal-title":"J Alzheimers Dis Other Demen"},{"key":"10.1016\/j.apsb.2024.11.016_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173554","article-title":"Alzheimer's disease: recent treatment strategies","volume":"887","author":"Vaz","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.apsb.2024.11.016_bib7","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.3390\/molecules25245789","article-title":"Comprehensive review on Alzheimer's disease","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2024.11.016_bib8","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3233\/JAD-140324","article-title":"Depression in Alzheimer\u2019s disease: epidemiology, mechanisms, and management","volume":"42","author":"Chi","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.apsb.2024.11.016_bib9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2174\/1567205053585846","article-title":"The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism","volume":"2","author":"Lipton","year":"2005","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.apsb.2024.11.016_bib10","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/837157","article-title":"Potential therapeutic strategies for Alzheimer's disease targeting or beyond \u03b2-Amyloid: insights from clinical trials","volume":"2014","author":"Jia","year":"2014","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.apsb.2024.11.016_bib11","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1523\/JNEUROSCI.23-20-07504.2003","article-title":"Anti-inflammatory drug therapy alters \u03b2-amyloid processing and deposition in an animal model of Alzheimer's disease","volume":"23","author":"Yan","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2024.11.016_bib12","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.ejmech.2007.06.009","article-title":"Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking","volume":"43","author":"Ravindra","year":"2008","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2024.11.016_bib13","first-page":"35","article-title":"Alzheimer's disease and Prion protein","volume":"2","author":"Jiayi Zhou","year":"2013","journal-title":"Intractable Rare Dis Res"},{"key":"10.1016\/j.apsb.2024.11.016_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173554","article-title":"Alzheimer's disease: recent treatment strategies","volume":"887","author":"Vaz","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.apsb.2024.11.016_bib15","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1471-2202-11-130","article-title":"Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse","volume":"11","author":"Chung","year":"2010","journal-title":"BMC Neurosci"},{"key":"10.1016\/j.apsb.2024.11.016_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3233\/JAD-2006-9202","article-title":"The key role of mitochondria in Alzheimer's disease","volume":"9","author":"Moreira","year":"2006","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.apsb.2024.11.016_bib17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1750-1326-2-22","article-title":"The Alzheimer's disease \u03b2-secretase enzyme, BACE1","volume":"2","author":"Cole","year":"2007","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.apsb.2024.11.016_bib18","first-page":"54","article-title":"Butyrylcholinesterase: structure and physiological importance","volume":"28","author":"\u00c7oku\u011fra\u015f","year":"2003","journal-title":"Turk J Biochem"},{"key":"10.1016\/j.apsb.2024.11.016_bib19","series-title":"Developing therapeutics for Alzheimer's disease: progress and challenges","first-page":"63","article-title":"\u03b3-Secretase inhibitors: from chemical probes to drug development","author":"Hur","year":"2016"},{"key":"10.1016\/j.apsb.2024.11.016_bib20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/cns.12696","article-title":"Calcitonin gene-related peptide (CGRP): a novel target for Alzheimer's disease","volume":"23","author":"Singh","year":"2017","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.apsb.2024.11.016_bib21","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1021\/cn3000907","article-title":"Phosphodiesterases as therapeutic targets for Alzheimer's disease","volume":"3","author":"Garc\u00eda-Osta","year":"2012","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.apsb.2024.11.016_bib22","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/sj.bjp.0706780","article-title":"Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder","volume":"148","author":"Abrams","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.apsb.2024.11.016_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuroscience.2014.01.025","article-title":"The role of D2-autoreceptors in regulating dopamine neuron activity and transmission","volume":"282","author":"Ford","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.apsb.2024.11.016_bib24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3233\/ADR-170003","article-title":"The GABA\u2013working memory relationship in Alzheimer's disease","volume":"1","author":"Mandal","year":"2017","journal-title":"J Alzheimers Dis Rep"},{"key":"10.1016\/j.apsb.2024.11.016_bib25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/nen.0b013e31802d6da9","article-title":"Expression of Nrf2 in neurodegenerative diseases","volume":"66","author":"Ramsey","year":"2007","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.apsb.2024.11.016_bib26","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3233\/JAD-201146","article-title":"Metabotropic glutamate receptors in Alzheimer\u2019s disease synaptic dysfunction: therapeutic opportunities and hope for the future","volume":"78","author":"Srivastava","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.apsb.2024.11.016_bib27","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/jcm8091377","article-title":"DJ-1 in Parkinson's disease: clinical insights and therapeutic perspectives","volume":"8","author":"Repici","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.apsb.2024.11.016_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2019.112384","article-title":"N-myc downstream-regulated gene 2 deficiency aggravates memory impairment in Alzheimer's disease","volume":"379","author":"Tao","year":"2020","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.apsb.2024.11.016_bib29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fnagi.2017.00007","article-title":"Protein tyrosine phosphatase 1B (PTP1B): a potential target for Alzheimer\u2019s therapy?.","volume":"9","author":"Vieira","year":"2017","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.apsb.2024.11.016_bib30","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.3390\/molecules26123724","article-title":"Role of monoamine oxidase activity in Alzheimer's disease: an insight into the therapeutic potential of inhibitors","volume":"26","author":"Behl","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2024.11.016_bib31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0197-4580(03)00117-9","article-title":"Regional NAD(P)H: quinone oxidoreductase activity in Alzheimer's disease","volume":"25","author":"SantaCruz","year":"2004","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.apsb.2024.11.016_bib32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-neuro-061010-113613","article-title":"Amyloid precursor protein processing and Alzheimer's disease","volume":"34","author":"O'Brien","year":"2011","journal-title":"Annu Rev Neurosci"},{"key":"10.1016\/j.apsb.2024.11.016_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200822010-00001","article-title":"The role of peroxisome proliferator-activated receptor-\u03b3 (PPAR\u03b3) in Alzheimer's disease: therapeutic implications","volume":"22","author":"Jiang","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.apsb.2024.11.016_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbi.2020.11.037","article-title":"Insight into the roles of CCR5 in learning and memory in normal and disordered states","volume":"92","author":"Necula","year":"2021","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.apsb.2024.11.016_bib35","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/ntr\/nty116","article-title":"Nicotinic acetylcholine receptor agonists for the treatment of Alzheimer's dementia: an update","volume":"21","author":"Hoskin","year":"2019","journal-title":"Nicotine Tob Res"},{"key":"10.1016\/j.apsb.2024.11.016_bib36","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3389\/fphar.2018.00440","article-title":"Targeting renin-angiotensin system against Alzheimer's disease","volume":"9","author":"Gebre","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2024.11.016_bib37","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/14728222.2018.1486823","article-title":"Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer\u2019s disease?.","volume":"22","author":"Deming","year":"2018","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.apsb.2024.11.016_bib38","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.18632\/aging.101518","article-title":"A promising connection between BDNF and Alzheimer's disease","volume":"10","author":"Giuffrida","year":"2018","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.apsb.2024.11.016_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2020.118664","article-title":"Glycogen synthase kinase-3 signaling in Alzheimer's disease","volume":"1867","author":"Lauretti","year":"2020","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"10.1016\/j.apsb.2024.11.016_bib40","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/pr.54.3.469","article-title":"Amyloid precursor protein, presenilin, and \u03b1-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease","volume":"54","author":"Suh","year":"2002","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.apsb.2024.11.016_bib41","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2174\/156802611795860942","article-title":"\u03b3-Secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes","volume":"11","author":"Imbimbo","year":"2011","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.apsb.2024.11.016_bib42","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1515\/revneuro-2014-0025","article-title":"Deciphering an interplay of proteins associated with amyloid \u03b21\u201342 peptide and molecular mechanisms of Alzheimer's disease","volume":"25","author":"Hern\u00e1ndez-Zimbr\u00f3n","year":"2014","journal-title":"Rev Neurosci"},{"key":"10.1016\/j.apsb.2024.11.016_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2018.00025","article-title":"Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer's disease","volume":"12","author":"Kametani","year":"2018","journal-title":"Front Neurosci"},{"key":"10.1016\/j.apsb.2024.11.016_bib44","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1471-4159.2009.06181.x","article-title":"The amyloid hypothesis for Alzheimer's disease: a critical reappraisal","volume":"110","author":"Hardy","year":"2009","journal-title":"J Neurochem"},{"key":"10.1016\/j.apsb.2024.11.016_bib45","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.brainres.2017.09.019","article-title":"Deferoxamine enhances alternative activation of microglia and inhibits amyloid beta deposits in APP\/PS1 mice","volume":"1677","author":"Zhang","year":"2017","journal-title":"Brain Res"},{"key":"10.1016\/j.apsb.2024.11.016_bib46","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.3390\/molecules25071659","article-title":"Oligomerization and conformational change turn monomeric \u03b2-amyloid and tau proteins toxic: their role in Alzheimer's pathogenesis","volume":"25","author":"Penke","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2024.11.016_bib47","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.0b013e3182309fa5","article-title":"A phase 2 randomized trial of ELND005, Scylla-inositol, in mild to moderate Alzheimer disease","volume":"77","author":"Salloway","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.apsb.2024.11.016_bib48","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40262-017-0608-3","article-title":"Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of Alzheimer's disease","volume":"57","author":"Hey","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.apsb.2024.11.016_bib49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3233\/JAD-2009-1044","article-title":"The Quest for small molecules as amyloid inhibiting therapies for Alzheimer\u2019s disease","volume":"17","author":"Amijee","year":"2009","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.apsb.2024.11.016_bib50","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3233\/JAD-2008-15207","article-title":"Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG)","volume":"15","author":"Mandel","year":"2008","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.apsb.2024.11.016_bib51","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0014-5793(93)80137-J","article-title":"An interaction of \u03b2-amyloid with aluminium in\u00a0vitro","volume":"324","author":"Exley","year":"1993","journal-title":"FEBS Lett"},{"key":"10.1016\/j.apsb.2024.11.016_bib52","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S1359-6454(99)00033-6","article-title":"Pre-precipitate clusters and precipitation processes in Al-Mg-Si alloys","volume":"47","author":"Murayama","year":"1999","journal-title":"Acta Mater"},{"key":"10.1016\/j.apsb.2024.11.016_bib53","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/0140-6736(91)92978-B","article-title":"Intramusculer desferrioxamine in patients with Alzheimer's disease","volume":"337","author":"McLachlan","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2024.11.016_bib54","doi-asserted-by":"crossref","first-page":"23223","DOI":"10.1074\/jbc.274.33.23223","article-title":"Aqueous dissolution of Alzheimer's disease A\u03b2 amyloid deposits by biometal depletion","volume":"274","author":"Cherny","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2024.11.016_bib55","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0896-6273(01)00317-8","article-title":"Treatment with a copper-zinc chelator markedly and rapidly inhibits \u03b2-amyloid accumulation in Alzheimer's disease transgenic mice","volume":"30","author":"Cherny","year":"2001","journal-title":"Neuron"},{"key":"10.1016\/j.apsb.2024.11.016_bib56","volume":"vol. 14","author":"Frederickson","year":"2001"},{"key":"10.1016\/j.apsb.2024.11.016_bib57","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M","article-title":"Soluble pool of A\u03b2 amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease","volume":"46","author":"Mclean","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1016\/j.apsb.2024.11.016_bib58","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/00005072-199908000-00001","article-title":"Intracellular APP processing and A\u03b2 production in Alzheimer's disease","volume":"58","author":"Wilson","year":"1999","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.apsb.2024.11.016_bib59","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1073\/pnas.94.8.4109","article-title":"Disaggregation of Alzheimer \u03b2-amyloid by site-directed mA\u03b2","volume":"94","author":"Solomon","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.apsb.2024.11.016_bib60","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3233\/JAD-2008-15404","article-title":"Anti-amyloid-\u03b2 immunotherapy in Alzheimer\u2019s disease: relevance of transgenic mouse studies to clinical trials","volume":"15","author":"Wilcock","year":"2008","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.apsb.2024.11.016_bib61","first-page":"508","article-title":"Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials","volume":"17","author":"Men\u00e9ndez-gonz\u00e1lez","year":"2011","journal-title":"Immunother Alzheimer\u2019s Dis"},{"key":"10.1016\/j.apsb.2024.11.016_bib62","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2217\/imt.09.3","article-title":"Immunotherapy for Alzheimer's disease","volume":"1","author":"Steinitz","year":"2009","journal-title":"Immunotherapy"},{"key":"10.1016\/j.apsb.2024.11.016_bib63","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3233\/JAD-2008-15404","article-title":"Anti-Amyloid-\u03b2 immunotherapy in Alzheimer\u2019s disease: relevance of transgenic mouse studies to clinical trials","volume":"15","author":"Wilcock","year":"2008","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.apsb.2024.11.016_bib64","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3233\/JAD-2006-9S348","article-title":"Immunotherapy for Alzheimer\u2019s disease","volume":"9","author":"Morgan","year":"2006","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.apsb.2024.11.016_bib65","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/jcpt.12112","article-title":"Potential novel targets for Alzheimer's pharmacotherapy: II. Update on secretase inhibitors and related approaches","volume":"39","author":"Mikulca","year":"2014","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.apsb.2024.11.016_bib66","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1517\/14712598.2012.688022","article-title":"Gantenerumab for the treatment of Alzheimer's disease","volume":"12","author":"Delrieu","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.apsb.2024.11.016_bib67","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2024.11.016_bib68","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/alz.12379","article-title":"Bayes analysis supports the null hypothesis of anti-amyloid beta therapy in Alzheimer\u2019s disease","volume":"17","author":"Richard","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.apsb.2024.11.016_bib69","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","article-title":"Anti-Amyloid-\u03b2 monoclonal antibodies for Alzheimer's disease: pitfalls and promise","volume":"83","author":"Dyck","year":"2018","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.apsb.2024.11.016_bib70","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.1471-4159.2001.00012.x","article-title":"Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in the brain","volume":"76","author":"Dovey","year":"2001","journal-title":"J Neurochem"},{"key":"10.1016\/j.apsb.2024.11.016_bib71","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1126\/science.1096187","article-title":"Intramembrane proteolysis: theme and variations","volume":"305","author":"Wolfe","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.apsb.2024.11.016_bib72","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1097-2765(00)00061-7","article-title":"Requirements for presenilin-dependent cleavage of notch and other transmembrane proteins","volume":"6","author":"Struhl","year":"2000","journal-title":"Mol Cell"},{"key":"10.1016\/j.apsb.2024.11.016_bib73","article-title":"Sampling the conformational space of the catalytic subunit of human \u03b3-secretase","volume":"4","author":"Bai","year":"2015","journal-title":"J Biophys Struct"},{"key":"10.1016\/j.apsb.2024.11.016_bib74","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3390\/ijms21030703","article-title":"Computer-aided drug design of \u03b2-secretase, \u03b3-secretase and anti-tau inhibitors for the discovery of novel Alzheimer's therapeutics","volume":"21","author":"Mouchlis","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2024.11.016_bib75","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1021\/acs.biochem.9b00401","article-title":"Structure and function of the \u03b3-secretase complex","volume":"58","author":"Wolfe","year":"2019","journal-title":"Biochemistry"},{"key":"10.1016\/j.apsb.2024.11.016_bib76","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3389\/fncel.2014.00427","article-title":"The \u03b3-secretase complex: from structure to function","volume":"8","author":"Zhang","year":"2014","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.apsb.2024.11.016_bib77","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nature14892","article-title":"An atomic structure of human \u03b3-secretase","volume":"525","author":"Bai","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2024.11.016_bib78","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41586-018-0813-8","article-title":"Structural basis of notch recognition by human \u03b3-secretase","volume":"565","author":"Yang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2024.11.016_bib79","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s12276-022-00754-8","article-title":"\u03b3-Secretase in Alzheimer's disease","volume":"54","author":"Hur","year":"2022","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.apsb.2024.11.016_bib80","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/19077","article-title":"Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and \u03b3-secretase activity","volume":"117","author":"Wolfe","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2024.11.016_bib81","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.2174\/092986711798194351","article-title":"Interacting with \u03b3-secretase for treating Alzheimer's disease: from inhibition to modulation","volume":"18","author":"Panza","year":"2011","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.apsb.2024.11.016_bib82","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/ana.24540","article-title":"GATA1-mediated transcriptional regulation of the c-secretase activating protein increases A\u03b2 formation in Down syndrome","volume":"79","author":"Chu","year":"2015","journal-title":"Am Neurol Asso"},{"key":"10.1016\/j.apsb.2024.11.016_bib83","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ejmech.2018.02.035","article-title":"Secretase inhibitors for the treatment of Alzheimer's disease: long road ahead","volume":"148","author":"Kumar","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2024.11.016_bib84","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A Phase 3 trial of semagacestat for treatment of Alzheimer's disease","volume":"369","author":"Doody","year":"2013","journal-title":"N Eng J Med"},{"key":"10.1016\/j.apsb.2024.11.016_bib85","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1001\/jamaneurol.2015.0607","article-title":"Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial","volume":"72","author":"Coric","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.apsb.2024.11.016_bib86","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1124\/jpet.109.152975","article-title":"Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor\u00a0of amyloid precursor protein \u03b3-secretase for the treatment\u00a0of Alzheimer's disease","volume":"331","author":"Martone","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.apsb.2024.11.016_bib87","first-page":"253","article-title":"Modelling and simulation of plasma A\u03b2 in humans after multiple oral doses of PF-3084014, a potent gamma-secretase inhibitor","volume":"5","author":"Qui","year":"2009","journal-title":"Pap Knowled Tow A Med Histo Doc"},{"key":"10.1016\/j.apsb.2024.11.016_bib88","first-page":"S79","article-title":"The gamma secretase inhibitor Mk-0752 acutely and significantly reduces CSF A\u03b2 40 concentrations in humans","volume":"2","author":"Stone","year":"2006","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.apsb.2024.11.016_bib89","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1474-4422(08)70090-5","article-title":"Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial","volume":"7","author":"Wilcock","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.apsb.2024.11.016_bib90","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial","volume":"302","author":"Green","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.apsb.2024.11.016_bib91","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jalz.2010.05.1958","article-title":"P3-415: E2012, a novel gamma-secretase modulator, decreases plasma amyloid-beta (A\u03b2) levels in humans","volume":"6","author":"Nagy","year":"2010","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.apsb.2024.11.016_bib92","series-title":"Eisai Co., Ltd. PharmaDeals review","volume":"vol. 2004","year":"2004"},{"key":"10.1016\/j.apsb.2024.11.016_bib93","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1124\/jpet.107.129007","article-title":"1-(3\u2032,4\u2032-Dichloro-2-fluoro[1,1\u2032-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel \u03b3-secretase modulator, reduces brain \u03b2-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity","volume":"323","author":"Imbimbo","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.apsb.2024.11.016_bib94","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1750-1326-7-61","article-title":"Modulation of \u03b3-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice","volume":"7","author":"Rogers","year":"2012","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.apsb.2024.11.016_bib95","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/j.jalz.2010.08.082","article-title":"P4-022: the gamma secretase modulator EVP-0015962 improves cognitive deficits in Tg2576 mice concomitant with decreases in A\u03b242","volume":"6","author":"Rogers","year":"2010","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.apsb.2024.11.016_bib96","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/sj.emboj.7600061","article-title":"Take five\u2014BACE and the \u03b3-secretase quartet conduct Alzheimer's amyloid \u03b2-peptide generation","volume":"23","author":"Haass","year":"2004","journal-title":"EMBO J"},{"key":"10.1016\/j.apsb.2024.11.016_bib97","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/med.21622","article-title":"BACE1 inhibitors: current status and future directions in treating Alzheimer's disease","volume":"40","author":"Moussa-Pacha","year":"2020","journal-title":"Med Res Rev"},{"key":"10.1016\/j.apsb.2024.11.016_bib98","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jnc.12715","article-title":"Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects","volume":"130","author":"Vassar","year":"2014","journal-title":"J Neurochem"},{"key":"10.1016\/j.apsb.2024.11.016_bib99","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00401-013-1152-3","article-title":"The Alzheimer's \u03b2-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques","volume":"126","author":"Kandalepas","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.apsb.2024.11.016_bib100","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1126\/science.290.5489.150","article-title":"Structure of the protease domain of memapsin 2 (\u03b2-secretase) complexed with an inhibitor","volume":"290","author":"Hong","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.apsb.2024.11.016_bib101","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1107\/S0907444911047251","article-title":"Flexibility of the flap in the active site of BACE1 as revealed by crystal structures and molecular dynamics simulations","volume":"68","author":"Xu","year":"2012","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.apsb.2024.11.016_bib102","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1128\/MCB.02185-07","article-title":"Crystal structure of an active form of BACE1, an enzyme responsible for amyloid \u03b2 protein production","volume":"28","author":"Shimizu","year":"2008","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.apsb.2024.11.016_bib103","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1021\/jm301659n","article-title":"Structure-based design of \u03b2-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease","volume":"56","author":"Yuan","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.11.016_bib104","doi-asserted-by":"crossref","first-page":"6765","DOI":"10.1039\/C3CS60460H","article-title":"BACE1 (\u03b2-secretase) inhibitors for the\u00a0treatment of Alzheimer's disease","volume":"43","author":"Ghosh","year":"2014","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.apsb.2024.11.016_bib105","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3233\/JAD-150834","article-title":"AZD3293: a novel, orally active BACE1 inhibitor with high potency and permeability and markedly slow off-rate kinetics","volume":"50","author":"Eketj\u00e4ll","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.apsb.2024.11.016_bib106","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jalz.2013.05.578","article-title":"P1\u2013351: a novel BACE inhibitor (PF-05297909): a two-part adaptive design to evaluate safety, pharmacokinetics, and pharmacodynamics for modifying beta-amyloid in a first-in-human study","volume":"9","author":"Bell","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.apsb.2024.11.016_bib107","doi-asserted-by":"crossref","first-page":"8823","DOI":"10.3390\/molecules27248823","article-title":"BACE1 inhibitors for Alzheimer\u2019s disease: the past, present and any future?.","volume":"27","author":"Bazzari","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2024.11.016_bib108","unstructured":"Alzforum. Therapeutics - LY2886721. Available from: wwwAlzforumOrg. 2019-23-5."},{"key":"10.1016\/j.apsb.2024.11.016_bib109","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized trial of Verubecestat for mild-to-moderate Alzheimer's disease","volume":"378","author":"Egan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2024.11.016_bib110","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13195-020-00614-5","article-title":"Long-term safety and tolerability of atabecestat (JNJ-5486191)","volume":"12","author":"Novak","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.apsb.2024.11.016_bib111","series-title":"Cognitive enhancement","first-page":"193","article-title":"Alzheimer's disease and mechanism-based attempts to enhance cognition","author":"Draffin","year":"2015"},{"key":"10.1016\/j.apsb.2024.11.016_bib112","series-title":"Alzheimer's disease. Subcellular biochemistry","first-page":"105","article-title":"The non-amyloidogenic pathway: structure and function of \u03b1-secretases","author":"Kojro","year":"2005"},{"key":"10.1016\/j.apsb.2024.11.016_bib113","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1756-6606-4-3","article-title":"APP processing in Alzheimer's disease","volume":"4","author":"Zhang","year":"2011","journal-title":"Mol Brain"},{"key":"10.1016\/j.apsb.2024.11.016_bib114","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nm0895-829","article-title":"Decreased \u03b1-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's disease","volume":"1","author":"Lannfelt","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2024.11.016_bib115","first-page":"585","article-title":"P3 beta-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain","volume":"149","author":"Higgins","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1016\/j.apsb.2024.11.016_bib116","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1093\/brain\/awf205","article-title":"A\u03b217\u201342 in Alzheimer's disease activates JNK and caspase-8 leading to neuronal apoptosis","volume":"125","author":"Wei","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.apsb.2024.11.016_bib117","doi-asserted-by":"crossref","first-page":"8167","DOI":"10.1073\/pnas.0609521104","article-title":"Involvement of \u03b2-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity","volume":"104","author":"Huifang","year":"2007","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.apsb.2024.11.016_bib118","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.2741\/4035","article-title":"Reviewing reasons for the decreased CSF Abeta 42 concentration in Alzheimer's disease","volume":"17","author":"Spies","year":"2012","journal-title":"Front Biosci"},{"key":"10.1016\/j.apsb.2024.11.016_bib119","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jacc.2019.12.033","article-title":"The Alzheimer's disease amyloid-beta hypothesis in cardiovascular aging and disease: JACC focus seminar","volume":"75","author":"Stakos","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.apsb.2024.11.016_bib120","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fnmol.2020.00137","article-title":"Targeting amyloidogenic processing of APP in Alzheimer's disease","volume":"13","author":"Zhao","year":"2020","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.apsb.2024.11.016_bib121","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.2933807","article-title":"Down Syndrome Alzheimer's linked: down syndrome, adults get Alzheimer-like changes in their brains and many become demented, leading researchers to ask about the connection","volume":"230","author":"Kolata","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.apsb.2024.11.016_bib122","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2174\/1567205014666170417111859","article-title":"Tau in Alzheimer's disease: mechanisms and therapeutic strategies","volume":"15","author":"Gao","year":"2018","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.apsb.2024.11.016_bib123","series-title":"Tau protein. Methods in molecular biology","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/978-1-4939-6598-4_6","article-title":"Detection and quantification methods for fibrillar products of in\u00a0vitro tau aggregation assays","author":"Nanavaty","year":"2017"},{"key":"10.1016\/j.apsb.2024.11.016_bib124","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-1-4939-6598-4_3","article-title":"Molecular dynamics simulation of tau peptides for the investigation of conformational changes induced by specific phosphorylation patterns","volume":"1523","author":"Gandhi","year":"2017","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.apsb.2024.11.016_bib125","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1242\/jcs.114.6.1179","article-title":"Inhibition of neuronal maturation in primary hippocampal neurons from \u03c4 deficient mice","volume":"114","author":"Ferreira","year":"2001","journal-title":"J Cell Sci"},{"key":"10.1016\/j.apsb.2024.11.016_bib126","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2174\/156720510793611592","article-title":"Tau in Alzheimer's disease and related tauopathies","volume":"7","author":"Khalid","year":"2010","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.apsb.2024.11.016_bib127","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40265-015-0529-0","article-title":"Tau biology and tau-directed therapies for Alzheimer's disease","volume":"76","author":"Bakota","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2024.11.016_bib128","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s10571-017-0574-1","article-title":"Tau proteins and tauopathies in Alzheimer's disease","volume":"38","author":"Chong","year":"2018","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.apsb.2024.11.016_bib129","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2589276","article-title":"Therapies for prevention and treatment of Alzheimer's disease","volume":"2016","author":"Mendiola-Precoma","year":"2016","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.apsb.2024.11.016_bib130","series-title":"Handbook of innovations in central nervous system regenerative medicine","first-page":"79","article-title":"Current clinical approaches in neurodegenerative diseases","author":"Gago","year":"2020"},{"key":"10.1016\/j.apsb.2024.11.016_bib131","first-page":"555","article-title":"Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets","volume":"21","author":"Winblad","year":"2008","journal-title":"Geriatr Psychiatry"},{"key":"10.1016\/j.apsb.2024.11.016_bib132","article-title":"Small-molecule inhibitors of GSK-3: structural insights and their application to Alzheimer\u2019s disease models","volume":"2012","author":"Kramer","year":"2012","journal-title":"Int J Alzheimers Dis"},{"key":"10.1016\/j.apsb.2024.11.016_bib133","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/j.1471-4159.2007.05194.x","article-title":"The GSK3 hypothesis of Alzheimer's disease","volume":"104","author":"Hooper","year":"2008","journal-title":"J Neurochem"},{"key":"10.1016\/j.apsb.2024.11.016_bib134","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.arr.2012.06.003","article-title":"Tau protein kinases: involvement in Alzheimer's disease","volume":"12","author":"Martin","year":"2013","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.apsb.2024.11.016_bib135","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/med.10011","article-title":"Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation","volume":"22","author":"Martinez","year":"2002","journal-title":"Med Res Rev"},{"key":"10.1016\/j.apsb.2024.11.016_bib136","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.nbd.2009.05.025","article-title":"A novel GSK-3 \u03b2 inhibitor reduces Alzheimer\u2019s pathology and rescues neuronal loss in vivo related papers","volume":"35","author":"Seren\u00f3","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.apsb.2024.11.016_bib137","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4088\/JCP.08m04606","article-title":"Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study","volume":"70","author":"Hampel","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.apsb.2024.11.016_bib138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/rns.2011.061","article-title":"GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer's disease","volume":"23","author":"Gao","year":"2012","journal-title":"Rev Neurosci"},{"key":"10.1016\/j.apsb.2024.11.016_bib139","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1471-4159.2004.02422.x","article-title":"Glycogen synthase kinase 3: a drug target for CNS therapies","volume":"89","author":"Bhat","year":"2004","journal-title":"J Neurochem"},{"key":"10.1016\/j.apsb.2024.11.016_bib140","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1523\/JNEUROSCI.5245-07.2008","article-title":"Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3; mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing","volume":"28","author":"Wen","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2024.11.016_bib141","doi-asserted-by":"crossref","first-page":"11500","DOI":"10.1523\/JNEUROSCI.3203-08.2008","article-title":"Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphatase","volume":"28","author":"Green","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2024.11.016_bib142","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2990.1978.tb00545.x","article-title":"Changes in brain cholinesterase in senile dementia of Alzheimer type","volume":"4","author":"Perry","year":"1978","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.apsb.2024.11.016_bib143","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1136\/bmj.2.6150.1457","article-title":"Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia","volume":"2","author":"Perry","year":"1978","journal-title":"Br Med J"},{"key":"10.1016\/j.apsb.2024.11.016_bib144","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/ageing\/afl027","article-title":"Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing","volume":"35","author":"Author","year":"2006","journal-title":"Age Ageing"},{"key":"10.1016\/j.apsb.2024.11.016_bib145","first-page":"1479","article-title":"Cholinesterase inhibitors as Alzheimer\u2019s therapeutics","volume":"20","author":"Sharma","year":"2019","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.apsb.2024.11.016_bib146","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/biom10010040","article-title":"Alzheimer's disease pharmacotherapy in relation to cholinergic system involvement","volume":"10","author":"Stanciu","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.apsb.2024.11.016_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.131398","article-title":"Anticholinesterase activities of novel indole-based hydrazide-hydrazone derivatives: design, synthesis, biological evaluation, molecular docking study and in silico ADME prediction","volume":"1247","author":"Co\u015far","year":"2022","journal-title":"J Mol Struct"},{"key":"10.1016\/j.apsb.2024.11.016_bib148","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2165\/00023210-199912040-00005","article-title":"Selectivity of cholinesterase inhibition: clinical implications for the treatment of Alzheimer's disease","volume":"12","author":"Weinstock","year":"1999","journal-title":"CNS Drugs"},{"key":"10.1016\/j.apsb.2024.11.016_bib149","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.coph.2005.01.014","article-title":"Acetylcholinesterase: \u2018classical\u2019 and \u2018non-classical\u2019 functions and pharmacology","volume":"5","author":"Silman","year":"2005","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.apsb.2024.11.016_bib150","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunctions","volume":"217","author":"Bartus","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.apsb.2024.11.016_bib151","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.bmc.2010.12.022","article-title":"Design, synthesis and evaluation of novel tacrine-multialkoxybenzene hybrids as dual inhibitors for cholinesterase and amyloid beta aggregation","volume":"19","author":"Luo","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2024.11.016_bib152","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ejmech.2014.01.017","article-title":"Indolinone-based acetylcholinesterase inhibitors: synthesis, biological activity and molecular modelling","volume":"84","author":"Akrami","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2024.11.016_bib153","first-page":"1","article-title":"Computational analysis of Alzheimer's disease drug targets","volume":"11","author":"Gupta","year":"2010","journal-title":"Curr Res Inf Pharm Sci"},{"key":"10.1016\/j.apsb.2024.11.016_bib154","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/BF00634455","article-title":"Effect of physostigmine on memory consolidation and retrieval processes in intact and nucleus basalis-lesioned rats","volume":"99","author":"Santucci","year":"1989","journal-title":"Psychopharmacol"},{"key":"10.1016\/j.apsb.2024.11.016_bib155","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1124\/mol.64.6.1295","article-title":"Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modelling","volume":"64","author":"Hirst","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.apsb.2024.11.016_bib156","first-page":"735","article-title":"Memantine is clinically well tolerated","volume":"38","author":"Parsons","year":"1999","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.apsb.2024.11.016_bib157","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3233\/JAD-160763","article-title":"Role of glutamate and NMDA receptors in Alzheimer\u2019s disease","volume":"57","author":"Wang","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.apsb.2024.11.016_bib158","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.neuropharm.2013.03.030","article-title":"NMDA receptors in nervous system diseases","volume":"74","author":"Zhou","year":"2013","journal-title":"Neuropharmacol"},{"key":"10.1016\/j.apsb.2024.11.016_bib159","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/1073858411435129","article-title":"Review diversity in NMDA receptor composition: many regulators, many consequences","volume":"19","author":"Sanz-clemente","year":"2013","journal-title":"Neuroscientist"},{"key":"10.1016\/j.apsb.2024.11.016_bib160","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s10072-016-2546-5","article-title":"Dysfunction of NMDA receptors in Alzheimer's disease","volume":"37","author":"Zhang","year":"2016","journal-title":"Neurol Sci"},{"key":"10.1016\/j.apsb.2024.11.016_bib161","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1093\/cercor\/bhn017","article-title":"Developmental regulation of the NMDA receptor subunits, NR3A and NR1, in human prefrontal cortex","volume":"18","author":"Henson","year":"2008","journal-title":"Cereb Cortex"},{"key":"10.1016\/j.apsb.2024.11.016_bib162","first-page":"150","article-title":"Alzheimer disease: the role of A\u03b2 in the glutamatergic system","volume":"1","author":"Campos-Pea","year":"2014","journal-title":"Neurochem"},{"key":"10.1016\/j.apsb.2024.11.016_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112447","article-title":"A comprehensive description of GluN2B-selective N-methyl-d-aspartate (NMDA) receptorantagonists","volume":"200","author":"Liu","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2024.11.016_bib164","doi-asserted-by":"crossref","first-page":"12603","DOI":"10.1523\/JNEUROSCI.1459-12.2012","article-title":"GluN2B-containing NMDA receptors promote wiring of adult-born neurons into olfactory bulb circuits","volume":"32","author":"Kelsch","year":"2012","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2024.11.016_bib165","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s10072-016-2546-5","article-title":"Dysfunction of NMDA receptors in Alzheimer's disease","volume":"37","author":"Zhang","year":"2016","journal-title":"Neurol Sci"},{"key":"10.1016\/j.apsb.2024.11.016_bib166","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.neuron.2014.01.035","article-title":"Distinct functional and pharmacological properties of triheteromeric GluN1\/GluN2A\/GluN2B NMDA receptors","volume":"81","author":"Hansen","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.apsb.2024.11.016_bib167","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116319","article-title":"A naturally occurring null variant of the NMDA type glutamate receptor NR3B subunit is a risk factor of schizophrenia","volume":"10","author":"Matsuno","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2024.11.016_bib168","doi-asserted-by":"crossref","first-page":"746","DOI":"10.2174\/156720512801322564","article-title":"N-Methyl d-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia, and Parkinson's disease","volume":"9","author":"Olivares","year":"2013","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.apsb.2024.11.016_bib169","first-page":"22","article-title":"NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease","volume":"59","author":"Farlow","year":"2004","journal-title":"Geriatrics"},{"key":"10.1016\/j.apsb.2024.11.016_bib170","doi-asserted-by":"crossref","first-page":"54","DOI":"10.14283\/jfa.2018.43","article-title":"The triggering receptor expressed on myeloid cells-2 (trem-2) as an expression of the relationship between microglia and Alzheimer's disease: a novel marker for a promising pathway to explore","volume":"8","author":"Gussago","year":"2019","journal-title":"J Frailty Aging"},{"key":"10.1016\/j.apsb.2024.11.016_bib171","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3390\/ijms19010318","article-title":"Microglia and aging: the role of the TREM2\u2013DAP12 and CX3CL1\u2013CX3CR1 axes","volume":"19","author":"Mecca","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2024.11.016_bib172","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/j.0022-0337.2012.76.11.tb05416.x","article-title":"Clinical\u00a0& immunological erythematosus patients characteristics in systemic lupus Maryam","volume":"76","author":"Aggarwal","year":"2012","journal-title":"J Dent Educ"},{"key":"10.1016\/j.apsb.2024.11.016_bib173","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1474-4422(18)30232-1","article-title":"The role of TREM2 in Alzheimer's disease and other neurodegenerative disorders","volume":"17","author":"Carmona","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.apsb.2024.11.016_bib174","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13024-017-0197-5","article-title":"TREM2 in neurodegenerative diseases","volume":"12","author":"Jay","year":"2017","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.apsb.2024.11.016_bib175","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S1474-4422(16)00127-7","article-title":"Genetic variations underlying Alzheimer's disease: evidence from genome-wide association studies and beyond","volume":"15","author":"Cuyvers","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.apsb.2024.11.016_bib176","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.neurobiolaging.2013.10.075","article-title":"Triggering receptor expressed on myeloid cells 2 variant is rare in late-onset Alzheimer's disease in Han Chinese individuals","volume":"35","author":"Yu","year":"2014","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.apsb.2024.11.016_bib177","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.15252\/emmm.201707672","article-title":"An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function","volume":"9","author":"Schlepckow","year":"2017","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.apsb.2024.11.016_bib178","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000430842","article-title":"Association study of the TREM2 gene and identification of a novel variant in exon 2 in Iranian patients with late-onset Alzheimer's disease","volume":"24","author":"Mehrjoo","year":"2015","journal-title":"Med Princ Pract"},{"key":"10.1016\/j.apsb.2024.11.016_bib179","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3233\/JAD-140225","article-title":"Lack of genetic association between TREM2 and late-onset Alzheimer\u2019s disease in a Japanese population","volume":"41","author":"Miyashita","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.apsb.2024.11.016_bib180","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/nn.3435","article-title":"CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology","volume":"16","author":"Bradshaw","year":"2013","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.apsb.2024.11.016_bib181","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/ng.439","article-title":"Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease","volume":"41","author":"Lambert","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.apsb.2024.11.016_bib182","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1172\/JCI77983","article-title":"TREM2 sustains microglial expansion during aging and response to demyelination","volume":"125","author":"Poliani","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2024.11.016_bib183","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrn.2016.7","article-title":"TREM2 variants: new keys to decipher Alzheimer disease pathogenesis","volume":"17","author":"Colonna","year":"2016","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.apsb.2024.11.016_bib184","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009093","article-title":"TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis","volume":"6","author":"Kleinberger","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2024.11.016_bib185","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/eji.201141679","article-title":"TREM-2, a triggering receptor expressed on myeloid cell-2, negatively regulates TLR responses in dendritic cells","volume":"42","author":"Ito","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.apsb.2024.11.016_bib186","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.neulet.2017.09.034","article-title":"ADAM17 is the main sheddase for the generation of human triggering receptors expressed in myeloid cells (hTREM2) ectodomain and cleaves TREM2 after histidine","volume":"660","author":"Feuerbach","year":"2017","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.apsb.2024.11.016_bib187","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1212\/01.WNL.0000160304.00003.CA","article-title":"The genetic causes of basal ganglia calcification, dementia, and bone cysts","volume":"64","author":"Ridha","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.apsb.2024.11.016_bib188","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1212\/WNL.56.11.1552","article-title":"CNS manifestations of Nasu\u2013Hakola disease frontal dementia with bone cysts","volume":"56","author":"Paloneva","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.apsb.2024.11.016_bib189","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/ahg.12000","article-title":"Initial Assessment of the pathogenic mechanisms of the recently identified Alzheimer risk loci","volume":"77","author":"Holton","year":"2013","journal-title":"Ann Hum Genet"},{"key":"10.1016\/j.apsb.2024.11.016_bib190","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/ncb1416","article-title":"Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis","volume":"8","author":"Takegahara","year":"2006","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.apsb.2024.11.016_bib191","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa1211851","article-title":"TREM2 variants in Alzheimer\u2019s disease","volume":"368","author":"Guerreiro","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2024.11.016_bib192","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.cell.2018.05.003","article-title":"Disease-associated microglia: a universal immune sensor of neurodegeneration","volume":"173","author":"Deczkowska","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2024.11.016_bib193","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.clinbiochem.2019.04.001","article-title":"Neuro-inflammation and anti-inflammatory treatment options for Alzheimer's disease","volume":"72","author":"Ozben","year":"2019","journal-title":"Clin Biochem"},{"key":"10.1016\/j.apsb.2024.11.016_bib194","first-page":"9557","article-title":"TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy","volume":"55","author":"Schoepp","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.apsb.2024.11.016_bib195","first-page":"2587","article-title":"Assessment of TREM2 rs75932628 association with Alzheimer's disease in a population-based sample: the Cache County Study","volume":"36","author":"Gonzalez","year":"2013","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.apsb.2024.11.016_bib196","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00401-016-1533-5","article-title":"Cerebrospinal fluid soluble TREM2 is higher in Alzheimer's disease and associated with mutation status","volume":"131","author":"Piccio","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.apsb.2024.11.016_bib197","doi-asserted-by":"crossref","first-page":"466","DOI":"10.15252\/emmm.201506123","article-title":"sTREM 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers","volume":"8","author":"Su\u00e1rez-calvet","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.apsb.2024.11.016_bib198","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ajhg.2012.07.023","article-title":"Genome-wide association and population genetic analysis of c-reactive protein in African American and Hispanic American women","volume":"91","author":"Reiner","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.apsb.2024.11.016_bib199","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1471-4159.2009.06130.x","article-title":"The surface-exposed chaperone, Hsp60, is an agonist of the microglial TREM2 receptor","volume":"110","author":"Stefano","year":"2009","journal-title":"J Neurochem"},{"key":"10.1016\/j.apsb.2024.11.016_bib200","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1471-4159.2009.06042.x","article-title":"A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia","volume":"109","author":"Hsieh","year":"2009","journal-title":"J Neurochem"},{"key":"10.1016\/j.apsb.2024.11.016_bib201","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.molmed.2013.06.004","article-title":"Bridging integrator 1 (BIN1): form, function, and Alzheimer's disease","volume":"19","author":"Tan","year":"2013","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.apsb.2024.11.016_bib202","article-title":"Expression of novel Alzheimer's disease risk genes in control and Alzheimer's disease brains","volume":"7","author":"Goate","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2024.11.016_bib203","doi-asserted-by":"crossref","first-page":"31453","DOI":"10.1074\/jbc.272.50.31453","article-title":"Structural analysis of the human BIN1 gene: evidence for tissue-specific transcriptional regulation and alternate RNA splicing","volume":"272","author":"Wechsler-Reya","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2024.11.016_bib204","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jmb.2005.05.046","article-title":"A structure-based model of the c-Myc\/Bin1 protein interaction shows alternative splicing of Bin1 and c-Myc phosphorylation are key binding determinants","volume":"351","author":"Pineda-Lucena","year":"2005","journal-title":"J Mol Biol"},{"key":"10.1016\/j.apsb.2024.11.016_bib205","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1128\/MMBR.70.1.37-120.2006","article-title":"The BAR domain proteins: molding membranes in fission, fusion, and phagy","volume":"70","author":"Ren","year":"2006","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.apsb.2024.11.016_bib206","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/ng0996-69","article-title":"BIN1 is a novel MYC-interacting protein with features of a tumor suppressor","volume":"14","author":"Sakamuro","year":"1996","journal-title":"Nat Genet"},{"key":"10.1016\/j.apsb.2024.11.016_bib207","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1128\/MCB.23.12.4295-4306.2003","article-title":"Targeted disruption of the murine bin1\/amphiphysin II gene does not disable endocytosis but results in embryonic cardiomyopathy with aberrant myofibril formation","volume":"23","author":"Muller","year":"2003","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.apsb.2024.11.016_bib208","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejcb.2008.08.006","article-title":"The membrane-tubulating potential of amphiphysin 2\/BIN1 is dependent on the microtubule-binding cytoplasmic linker protein 170 (CLIP-170)","volume":"88","author":"Meunier","year":"2009","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.apsb.2024.11.016_bib209","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/(SICI)1097-4644(19990901)74:3<313::AID-JCB1>3.0.CO;2-Z","article-title":"Induction of apoptosis and differentiation in neuroblastoma and astrocytoma cells by the overexpression of Bin1, a novel Myc interacting protein","volume":"74","author":"Galderisi","year":"1999","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.apsb.2024.11.016_bib210","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1038\/sj.onc.1203681","article-title":"The c-Myc-interacting adaptor protein Bin1 activates a caspase-independent cell death program","volume":"19","author":"Elliott","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2024.11.016_bib211","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cell.2007.12.032","article-title":"Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7","volume":"132","author":"Wajapeyee","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2024.11.016_bib212","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.gde.2011.02.002","article-title":"Genetics of Alzheimer\u2019s disease: new evidences for an old hypothesis?.","volume":"21","author":"Lambert","year":"2011","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.apsb.2024.11.016_bib213","article-title":"Alzheimer\u2019s disease: APP, gamma-secretase, APOE, CLU, CR1, PICALM, ABCA7, BIN1, CD2AP, CD33, EPHA1, and MS4A2, and their relationships with herpes simplex, C. pneumoniae, other suspect pathogens, and the immune system","volume":"1","author":"Carter","year":"2011","journal-title":"Int J Alzheimers Dis"},{"key":"10.1016\/j.apsb.2024.11.016_bib214","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.15252\/emmm.201707672","article-title":"TREM-2, triggering receptor expressed on myeloid cell-2, negatively regulates TLR responses in dendritic cells","volume":"9","author":"Schlepckow","year":"2017","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.apsb.2024.11.016_bib215","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/mp.2013.1","article-title":"Increased expression of BIN1 mediates Alzheimer's genetic risk by modulating tau pathology","volume":"18","author":"Chapuis","year":"2013","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.apsb.2024.11.016_bib216","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3233\/JAD-2010-100684","article-title":"Oren-gedoku-to and its constituents with therapeutic potential in Alzheimer\u2019s disease inhibit indoleamine 2,3-dioxygenase activity in vitro","volume":"22","author":"Yu","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.apsb.2024.11.016_bib217","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.bbadis.2011.08.013","article-title":"Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: the case for isradipine","volume":"1812","author":"Anekonda","year":"2011","journal-title":"Biochim Biophys Acta, Mol Basis Dis"},{"key":"10.1016\/j.apsb.2024.11.016_bib218","first-page":"59","article-title":"Cell \u2018\u201cself-eating\u201d\u2019 (autophagy) mechanism in Alzheimer's disease","volume":"77","author":"Funderburk","year":"2010","journal-title":"J Transl Pers Med"},{"key":"10.1016\/j.apsb.2024.11.016_bib219","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/13543784.2022.2117605","article-title":"COR388 (atuzaginstat): an investigational gingipain inhibitor for the treatment of Alzheimer's disease","volume":"31","author":"Sabbagh","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.apsb.2024.11.016_bib220","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3233\/JAD-191337","article-title":"Associations of infectious agents with Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"75","author":"Ou","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.apsb.2024.11.016_bib221","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/ageing\/16.5.311","article-title":"A sero-epidemiological study of conventional infectious agents in Alzheimer's disease","volume":"16","author":"Renvoize","year":"1987","journal-title":"Age Ageing"},{"key":"10.1016\/j.apsb.2024.11.016_bib222","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jalz.2008.12.001","article-title":"Alzheimer\u2019s disease and infection: do infectious agents contribute to the progression of Alzheimer\u2019s disease?.","volume":"5","author":"Honjo","year":"2009","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.apsb.2024.11.016_bib223","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.4155\/fmc-2021-0036","article-title":"Small-molecule inhibitors of carboxylesterase Notum","volume":"13","author":"Zhao","year":"2021","journal-title":"Future Med Chem"},{"key":"10.1016\/j.apsb.2024.11.016_bib224","doi-asserted-by":"crossref","first-page":"12942","DOI":"10.1021\/acs.jmedchem.0c01391","article-title":"5-Phenyl-1,3,4-oxadiazol-2(3H)-ones are potent inhibitors of notum carboxylesterase activity identified by the optimization of a crystallographic fragment screening hit","volume":"63","author":"Mahy","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.11.016_bib225","first-page":"187","article-title":"Europe PMC funders group notum deacylates Wnts to suppress signalling activity Europe PMC funders author manuscripts","volume":"519","author":"Kakugawa","year":"2015","journal-title":"PMC"},{"key":"10.1016\/j.apsb.2024.11.016_bib226","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3389\/fncel.2019.00227","article-title":"Wnt signaling deregulation in the aging and Alzheimer's brain","volume":"13","author":"Palomer","year":"2019","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.apsb.2024.11.016_bib227","doi-asserted-by":"crossref","first-page":"12386","DOI":"10.18632\/oncotarget.7157","article-title":"NOTUM is a potential pharmacodynamic biomarker of Wnt pathway inhibition","volume":"7","author":"Madan","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2024.11.016_bib228","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1101\/gad.991802","article-title":"Wingful, an extracellular feedback inhibitor of Wingless","volume":"16","author":"Gerlitz","year":"2002","journal-title":"Genes Dev"},{"key":"10.1016\/j.apsb.2024.11.016_bib229","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S1534-5807(02)00180-6","article-title":"HSPG modification by the secreted enzyme Notum shapes the Wingless morphogen gradient","volume":"2","author":"Gir\u00e1ldez","year":"2002","journal-title":"Dev Cell"},{"key":"10.1016\/j.apsb.2024.11.016_bib230","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1021\/acs.jmedchem.0c01974","article-title":"Carboxylesterase notum is a druggable target to modulate wnt signaling","volume":"64","author":"Bayle","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.11.016_bib231","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.devcel.2004.08.005","article-title":"Opposing activities of Dally-like glypican at high and low levels of wingless morphogen activity","volume":"7","author":"Kreuger","year":"2004","journal-title":"Dev Cell"},{"key":"10.1016\/j.apsb.2024.11.016_bib232","doi-asserted-by":"crossref","first-page":"11354","DOI":"10.1021\/acs.jmedchem.1c00701","article-title":"Structural insights into Notum covalent inhibition","volume":"64","author":"Zhao","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.11.016_bib233","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1021\/acsmedchemlett.8b00191","article-title":"Selective irreversible inhibitors of the Wnt-deacylating enzyme notum developed by\u00a0activity-based protein profiling","volume":"9","author":"Suciu","year":"2018","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.apsb.2024.11.016_bib234","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41586-019-1383-0","article-title":"Notum produced by paneth cells attenuates regeneration of aged intestinal epithelium","volume":"571","author":"Pentinmikko","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2024.11.016_bib235","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107805","article-title":"Single-cell profiling and scope-seq reveal lineage dynamics of adult ventricular-subventricular zone neurogenesis and notum as a key regulator","volume":"31","author":"Mizrak","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2024.11.016_bib236","doi-asserted-by":"crossref","DOI":"10.1111\/jpi.12630","article-title":"Structural characterization of melatonin as an inhibitor of the Wnt deacylase Notum","volume":"68","author":"Zhao","year":"2020","journal-title":"J Pineal Res"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383524004507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383524004507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:16:57Z","timestamp":1762604217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383524004507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":236,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2211383524004507"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2024.11.016","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive investigation of multiple targets in the development of newer drugs for the Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2024.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}